Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12887770 | 1.00 | ADK (0.65) | ADKHIF1ATSHRHSPA8CDK1 | |
| SCHEMBL12870508 | 1.00 | ADK (0.65) | ADKHIF1ATSHRHSPA8CDK1 | |
| SCHEMBL4867164 | 0.87 | ADK (0.61) | ADKHIF1ATSHRHSPA8CDK1 | |
| SCHEMBL4870572 | 0.87 | ADK (0.61) | ADKHIF1ATSHRHSPA8CDK1 | |
| SCHEMBL4867832 | 0.83 | ADK (0.68) | ADKHIF1AHSPA8CA1CA2 | |
| SCHEMBL14028811 | 0.83 | ADK (0.68) | ADKHIF1AHSPA8CA1CA2 | |
| SCHEMBL17612669 | 0.81 | ADK (0.65) | ADKHIF1ATSHRHSPA8CA1 | |
| SCHEMBL9805553 | 0.81 | ADK (0.65) | ADKHIF1AHSPA8DPP4 | |
| SCHEMBL17612673 | 0.81 | ADK (0.65) | ADKHIF1ATSHRHSPA8CA1 | |
| SCHEMBL9805237 | 0.81 | ADK (0.65) | ADKHIF1AHSPA8DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | claimed |
| EP-1534726-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC Therapeutics, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2004-04-08 | — | — | US | claimed |
| WO-2004009609-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7291603-B2 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | NSUN2, UPF1, NSUN3 | ADK 523/4885HIF1A 3008/4885TSHR 3690/4885 |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885HIF1A 1324/4885TSHR 4328/4885 |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885HIF1A 1324/4885TSHR 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.